Rare Is Everywhere.
Let’s Treat It.
We are a clinical-stage company building the leading therapies to serve people with rare genetic skin diseases.
Palvella (pɑlʋelːɑ)
: a Finnish word meaning “serve”
Palvella Therapeutics is driven by a singular goal: to help every individual suffering from rare genetic skin diseases find a treatment. Founded in 2015, Palvella’s team of passionate, highly credentialed collaborators is dedicated to making transformative new treatments a reality for thousands.
A Visible Need
1 in 10 Americans have a rare disease.1
Genetic skin diseases are visible, often debilitating, and traditionally difficult to treat through current treatment protocols. Among nearly 600 rare dermatologic diseases, less than 2 percent currently have an FDA-approved therapy.
A Clearer Future Is on the Horizon
Palvella’s researchers have identified new breakthroughs in the treatment of rare diseases enabled by Palvella’s QTORIN™ platform. Targeted therapies that have the potential to be high clinical impact to patients living with serious, rare genetic skin diseases are now within reach.
These therapies have the potential to impact hundreds of thousands living with rare genetic skin diseases.
Our Platform:
QTORIN™
Developing targeted topical treatments for certain rare skin diseases is hindered by technical challenges including achieving therapeutic drug concentrations and chemical stability while minimizing system absorption of the drug—issues we’re addressing with Palvella’s QTORIN™ platform.
Since its invention in 2017, the QTORIN™ platform has undergone several years of research and investment, emerging as a new, revolutionary drug delivery platform. Applied topically rather than taken orally, QTORIN™ has the power to transform the current treatment landscape—and transform lives in the process.
Groundbreaking Treatment
The QTORIN™ platform is a patented and versatile platform designed to rapidly deliver new therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of rare skin diseases.
Rapid Advancements
With positive phase 2 clinical trials and Fast Track and Breakthrough Therapy designations by the FDA, the future treatment options for rare genetic skin disorders are bright.
Expansive Reach
Palvella’s initial product candidate, QTORIN 3.9% rapamycin anhydrous gel, has the potential to positively impact hundreds of thousands of patients living around the world with mTOR-driven rare genetic skin diseases.
Innovation is here.
Be a part of what’s next in the future of rare skin disease treatment.
Corporate Profile
Palvella Therapeutics is a biotechnology company specializing in developing and commercializing medicines for patients with rare dermatological diseases. Headquartered in Wayne, Pennsylvania, Palvella’s leadership and scientific management teams have a proven track record of success and a strong commitment to leading the way in the advancement of targeted treatments for rare genodermatoses.
Investors
We are grateful for the confidence and support of these investors:
References
1. “1 in 10 Americans Have a Rare Disease, but Few Have Treatments.” STAT, AstraZeneca Rare Disease, 21 Dec. 2023, Source.